ALKEM.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (9 May 2024 @ 06:00):

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally...

Stats
Today's Volume	215 979
Average Volume	228 709
Market Cap	605.91B
EPS	INR49.76 ( 2024-02-09 )
Next earnings date	( INR0 ) 2024-05-16
Last Dividend	INR10.00 ( 2023-08-09 )
Next Dividend	INR0 ( N/A )
P/E	38.53
ATR14	INR5.99 (0.12%)

Volume Correlation

Long: -0.50 (neutral)

Short: 0.73 (moderate)

Signal:(47.534) Neutral

Alkem Laboratories Correlation

10 Most Positive Correlations
MASPTOP50.NS	0.902
MAFANG.NS	0.885
BAJAJ-AUTO.NS	0.881
HARIOMPIPE.NS	0.876
MON100.NS	0.869
SETF10GILT.NS	0.868
DATAPATTNS.NS	0.868
MANINDS.NS	0.865
MOGSEC.NS	0.862
GTNTEX.NS	0.861

10 Most Negative Correlations
MOHOTAIND.NS	-0.877
ROLTA.NS	-0.865
SECURKLOUD.NS	-0.864
SUMICHEM.NS	-0.861
RUSHIL.NS	-0.852
CLNINDIA.NS	-0.849
BAFNAPH.NS	-0.848
LICI.NS	-0.847
DPSCLTD.NS	-0.846
EASTSILK.NS	-0.841

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Alkem Laboratories Correlation - Currency/Commodity

-0.75
( moderate negative )

-0.06
( neutral )

-0.59
( weak negative )

-0.24
( neutral )

-0.87
( strong negative )

0.59
( weak )

Alkem Laboratories Financials

Annual	2022
Revenue:	INR115.99B
Gross Profit:	INR66.92B (57.70 %)
EPS:	INR82.31

FY	2022
Revenue:	INR115.99B
Gross Profit:	INR66.92B (57.70 %)
EPS:	INR82.31

FY	2022
Revenue:	INR105.12B
Gross Profit:	INR62.29B (59.25 %)
EPS:	INR137.63

FY	2021
Revenue:	INR87.47B
Gross Profit:	INR51.61B (59.00 %)
EPS:	INR132.57

Financial Reports:

No articles found.

Alkem Laboratories Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR4.00 (N/A)	INR0 (N/A)	INR25.00 (N/A)	INR0 (N/A)	INR10.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Alkem Laboratories Dividend Information - Dividend Junior

Dividend Sustainability Score: 3.90 - low (29.79%) | Divividend Growth Potential Score: 5.48 - Stable (9.62%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR9.70	2016-03-18
Last Dividend	INR10.00	2023-08-09
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	15	--
Total Paid Out	INR177.70	--
Avg. Dividend % Per Year	0.71%	--
Score	2.84	--
Div. Sustainability Score	3.90
Div.Growth Potential Score	5.48
Div. Directional Score	4.69	--

Next Divdend (Est)
(2024-08-08)

INR8.69 Estimate 7.41 %

Dividend Stability

0.30 Very Poor

Dividend Score

2.84

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR13.00	0.65%
2019	INR16.00	0.83%
2020	INR25.00	1.20%
2021	INR30.00	1.02%
2022	INR34.00	0.93%
2023	INR35.00	1.17%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SHANTIGEAR.NS	Dividend Junior	2023-07-11	Annually	23	1.02%
MANALIPETC.NS	Dividend Junior	2023-09-15	Annually	18	1.50%
GPPL.NS	Dividend Knight	2023-07-26	Semi-Annually	9	2.89%
AXISBANK.NS	Dividend Junior	2023-07-06	Sporadic	26	0.06%
TTKPRESTIG.NS	Dividend Junior	2023-07-21	Annually	20	0.43%
PKTEA.NS	Dividend Junior	2023-09-18	Sporadic	15	0.24%
JKLAKSHMI.NS	Dividend Junior	2023-08-11	Annually	18	0.50%
DHRUV.NS	Dividend Junior	2023-09-05	Insufficient data to determine frequency	2	0.15%
SOMANYCERA.NS	Dividend Junior	2023-08-18	Annually	23	0.39%
MMP.NS	Dividend Junior	2023-08-18	Annually	4	0.49%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.125	1.500	7.51	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.163	1.500	9.30	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	18.58	1.000	4.23	4.23	[3 - 30]
operatingCashFlowPerShareTTM	49.21	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	49.21	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.597	1.000	3.38	3.38	[0.2 - 0.8]
operatingProfitMarginTTM	0.168	1.000	8.63	8.63	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.90

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	39.16	1.000	6.15	0	[1 - 100]
returnOnEquityTTM	0.163	2.50	9.55	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	49.21	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.873	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	49.21	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	10.26	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0466	1.000	-1.336	0	[0.1 - 0.5]
Total Score				5.48

Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the development, manufacture, and sale of pharmaceutical and nutraceutical products in India and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, dermatology, cardiac, respiratory, gastro-intestinal, central nervous system, oncology, urology, and gynaecology, as well as vitamins, minerals, and nutrients; and pain analgesic, anti-diabetic, and neurology products. It also provides pregnancy detection kits and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.